Effect of bifid triple viable bacteria combined with ursodeoxycholic acid on liver function and serum procalcitonin level in patients with liver cirrhosis
-
摘要: 目的:观察双歧三联活菌联合熊去氧胆酸对肝硬化患者的肝功能及血清降钙素原水平的影响。方法:58例肝硬化患者,按照随机数字表法分为观察组(n=30)和对照组(n=28),2组在常规治疗基础上,对照组采用双歧三联活菌(3粒,2次/d)治疗,观察组采用双歧三联活菌联合熊去氧胆酸(250 mg,3次/d)治疗。1个月后观察2组治疗疗效、治疗前后肝功能、凝血功能,Child-Pugh评分、降钙素原(PCT)水平。结果:治疗后,观察组总有效率显著高于对照组(P<0.01);ALT、AST、TBil、I-Bil、DBIL水平均显著低于对照组(P<0.01);PTA显著高于对照组(P<0.01);PT、APTT水平显著低于对照组(P<0.01);Child-Pugh评分、PCT水平显著低于对照组(P<0.01)。结论:双歧三联活菌联合熊去氧胆酸可有效改善肝硬化患者的临床症状,可降低血清PCT水平,降低血生化值,改善肝功能和凝血功能。Abstract: Objective: To observe the effect of Bifid Triple Viable Bacteria combined with ursodeoxycholic acid on liver function and serum procalcitonin level in patients with liver cirrhosis.Methods: Fifty-eight cases of Cirrhosis. According to random number table, those patients were divided into the observation group(n=30) and the control group(n=28). On the basis of routine treatment, The control group was treated with Bifid Triple Viable Bacteria(3 capsules, twice a day), while the observation group treated with Bifid Triple Viable Bacteria combined with ursodeoxycholic acid(250 mg, 3 times a day). One month later, the therapeutic effect, liver function, coagulation function, Child-Pugh score and procalcitonin(PCT) level of the two groups were observed before and after treatment.Results: After treatment, The total remission rate in the observation group was significantly higher the control group(P<0.05). The levels of ALT, AST, TBil, I-Bil, DBIL were significantly lower than the control group(P<0.01). PTA was significantly higher than the control group(P<0.01). The levels of PT and APTT were significantly lower than the control group(P<0.01). Child-Pugh score and PCT levels were significantly lower than the control group(P<0.01).Conclusion: Bifid Triple Viable Bacteria combined with ursodeoxycholic acid can effectively improve the clinical symptoms of patients with liver cirrhosis, reduce serum procalcitonin level, reduce blood biochemical value, improve liver function and coagulation function.
-
Key words:
- bifidobacteria /
- ursodeoxycholic acid /
- cirrhosis /
- liver function /
- serum procalcitonin
-
-
[1] 俞逊婕,翁明钢,梁赣锋,等.双歧杆菌四联活菌片联合谷氨酰胺对酒精性肝硬化患者肠黏膜屏障功能的保护作用[J].中国微生态学杂志,2017,29(2):186-188,191.
[2] Dillon A,Egan K,Kevane B,et al.Liver stiffness and thrombin generation in compensated cirrhosis[J].Res Practi Thromb Haemost,2019,3(2):291-297.
[3] 余祝,罗利飞.双歧三联活菌胶囊对肝硬化自发性细菌性腹膜炎患者肠粘膜屏障功能的保护作用[J].实用药物与临床,2013,16(12):1176-1178.
[4] Wilde B,Katsounas A.Immune Dysfunction and Albumin-Related Immunity in Liver Cirrhosis[J].Mediators Inflamma,2019,2019(4):1-9.
[5] 张静雯,时永全,韩英.肝硬化的治疗进展[J].临床肝胆病杂志,2015,31(3):465-468.
[6] Ozcelik F.The association of bile acids and adrenomedullin,which can lead to hyperdynamic circulation in cirrhosis[J].Europ J Gastroenterol Hepatol,2019,31(1):141.
[7] 吴继雄,邓亚芳,方亮,等.双歧三联活菌联合乳果糖治疗肝硬化肠源性内毒素血症的疗效及其对肝功能和凝血功能的影响[J].疑难病杂志,2016,15(5):453-455,459.
[8] Butterworth,Roger F.Hepatic Encephalopathy in Cirrhosis:Pathology and Pathophysiology[J].Drugs,2019,(3):1-5.
[9] 肖丹,贾业贵.双歧三联活菌辅助治疗对肝硬化患者肠道菌群、血浆内毒素及肠黏膜屏障功能的影响[J].药物流行病学杂志,2016,25(6):339-341,353.
[10] Inka M,Miguel AR,Ana de H,et al.Outcomes of Bariatric Surgery in Patients with Cirrhosis[J].Obesity Surgery,2019,29(2):585-592.
[11] 孙永强.原发性胆汁性肝硬化的机制研究及愈肝方联合熊去氧胆酸的疗效评价[D].西安:第四军医大学,2014.
[12] 任晓丽.维生素D联合熊去氧胆酸治疗原发性胆汁性肝硬化的疗效分析:回顾性临床研究[D].西安:第四军医大学,2015.
[13] 毛辉,李海强.血清降钙素原与C-反应蛋白联合检测在肝硬化并肺部感染患者中的诊断价值[J].标记免疫分析与临床,2016,23(12):1446-1449.
[14] 郭锐,覃进.随机对照试验研究熊去氧胆酸治疗原发性胆汁性肝硬化患者的疗效及安全性[J].实用肝脏病杂志,2017,20(1):109-110.
[15] 王立,盛吉芳,郑春华,等.血清降钙素原与内毒素对肝硬化患者腹水感染的诊断分析[J].中华医院感染学杂志,2016,26(1):43-45.
-
计量
- 文章访问数: 250
- PDF下载数: 70
- 施引文献: 0
下载: